At least one disgruntled co-author has triggered the retraction of a paper presenting a novel approach to treating a rare, genetically inherited condition.
The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 appeared to partially treat FXS in mice in the study, published earlier this year.
The journal’s notice says the paper was retracted over a dispute among authors about the order in which they are listed on the paper: Continue reading Dispute over author order torpedoes paper on syndrome linked to autism